ArticleTechnology in cancer research & treatment2019
MiR-122 Promotes the Development of Colon Cancer by Targeting
Article in Technology in cancer research & treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Analysis of Risk Factors and Assessment of miRNA-122 as a Novel Biomarker for Colon Cancer in Egyptian Patients.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Impact of microRNA variants on PI3K/AKT signaling in triple-negative breast cancer: comprehensive review.Medical oncology (Northwood, London, England) · 2024Review
- The Impact of miR-122 on Cancer.Current pharmaceutical biotechnology · 2024Review
- NONHSAG028908.3 sponges miR‑34a‑5p to promote growth of colorectal cancer via targeting ALDOA.Oncology reports · 2023Article
- Plasma small-extracellular vesicles enriched in miR-122-5p promote disease aggressiveness in pediatric anaplastic large-cell lymphoma.Cancer communications (London, England) · 2023Article
- Molecular Subtyping and Survival Analysis of Osteosarcoma Reveals Prognostic Biomarkers and Key Canonical Pathways.Cancers · 2023Article
- MicroRNA-122 in human cancers: from mechanistic to clinical perspectives.Cancer cell international · 2023Review
- RNA-Interference-Mediated miR-122-Based Gene Regulation in Colon Cancer, a Structural In Silico Analysis.International journal of molecular sciences · 2022Article
- Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity.Scientific reports · 2022Article
- Epigenetic Small-Molecule Modulators Targeting Metabolic Pathways in Cancer.Sub-cellular biochemistry · 2022Article
- Targeting the lncRNA FGD5-AS1/miR-497-5p/PD-L1 Axis Inhibits Malignant Phenotypes in Colon Cancer (CC).BioMed research international · 2022Article
- Bioinformatics Analysis of Differential Gene and MicroRNA Expression in Lung Adenocarcinoma: Genetic Effects on Patient Prognosis, as Indicated by the TCGA Database.Cancer informatics · 2022Article
- Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer.Journal of healthcare engineering · 2022Article
- Long non-coding RNA AC122108.1 promotes lung adenocarcinoma brain metastasis and progression through the Wnt/β-catenin pathway by directly binding to aldolase A.Annals of translational medicine · 2021Article
- miR-1253, a novel tumor suppressor gene in colon cancer, is associated with poor patients prognosis.Clinical and experimental medicine · 2021Article
- Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment.Biology · 2021Review
- Targeting the Metabolic Adaptation of Metastatic Cancer.Cancers · 2021Review
- Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome.Frontiers in veterinary science · 2021Article
- Low miR-1273a expression predicts poor prognosis of colon cancer and facilitates tumor cell proliferation, migration, and invasion.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
Corrections and comments
- Retraction · 2023-04-19Duplication of/in Image · Lack of IRB/IACUC Approval and/or Compliance · Results Not Reproducible · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/9A56A5A1B43D233A79E2AD7E52E365?utm_source=Chrome%26utm_medium=BrowserExtension%26utm_campaign=Chrome
- Retracted
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-coding RNAs, originally considered junk gene products, have taken center stage in view of their significant involvement in a spectrum of biological processes during human development, thereby offering novel therapeutic targets for improvement of treatment options. Accumulating evidence has demonstrated non-coding RNA dysfunction across various human cancers. In particular, microRNAs have emerged as key regulatory molecules in cancer biology. MicroRNAs are noninvasive, readily accessible biomarkers that can be effectively applied for diagnosis and prognosis of different tumor types, including colon cancer. In this study, we reanalyzed the available data with bioinformatics tools to identify differentially expressed microRNAs in colon cancer cells. The top 3 upregulated microRNAs (miR-10, miR-199, and miR-122) in colon cancer cells were further validated in tissues of clinical patients via reverse transcription-quantitative polymerase chain reaction. Our results showed that miR-122 significantly promotes the proliferation and invasion ability of SW480 and SW620 cells through inhibition of Aldolase, Fructose-Bisphosphate A (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.